Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Adrenal Cortex Hormones
/ adverse effects
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
/ adverse effects
Biological Products
/ adverse effects
Cytokine Release Syndrome
/ drug therapy
Dexamethasone
/ adverse effects
Female
Humans
Immunotherapy, Adoptive
/ adverse effects
Lymphoma, Large B-Cell, Diffuse
/ therapy
Male
Middle Aged
axi-cel
chimaeric antigen receptor-T cell
corticosteroids
cytokine release syndrome
large B-cell lymphoma
prophylaxis
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
25
11
2020
accepted:
21
03
2021
pubmed:
24
7
2021
medline:
16
12
2021
entrez:
23
7
2021
Statut:
ppublish
Résumé
ZUMA-1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi-cel), an autologous CD19-directed chimaeric antigen receptor (CAR)-T cell therapy, in refractory large B-cell lymphoma. To reduce treatment-related toxicity, several exploratory safety management cohorts were added to ZUMA-1. Specifically, cohort 6 investigated management of cytokine release syndrome (CRS) and neurologic events (NEs) with prophylactic corticosteroids and earlier corticosteroid and tocilizumab intervention. CRS and NE incidence and severity were primary end-points. Following leukapheresis, patients could receive optional bridging therapy per investigator discretion. All patients received conditioning chemotherapy (days -5 through -3), 2 × 10
Identifiants
pubmed: 34296427
doi: 10.1111/bjh.17527
pmc: PMC8457222
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Antineoplastic Agents, Immunological
0
Biological Products
0
Dexamethasone
7S5I7G3JQL
axicabtagene ciloleucel
U2I8T43Y7R
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
690-700Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 Kite, a Gilead Company. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
CNS Drugs. 2018 Dec;32(12):1091-1101
pubmed: 30387077
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
Ann Transl Med. 2019 Jan;7(1):16
pubmed: 30788363
J Clin Oncol. 2020 Sep 20;38(27):3119-3128
pubmed: 32401634
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Blood Adv. 2020 Oct 13;4(19):4898-4911
pubmed: 33035333
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Blood Adv. 2020 Nov 24;4(22):5607-5615
pubmed: 33180899
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
J Allergy Clin Immunol. 2020 Nov;146(5):940-948
pubmed: 32771558
Ther Clin Risk Manag. 2019 Feb 28;15:323-335
pubmed: 30880998
Am Soc Clin Oncol Educ Book. 2019 Jan;39:433-444
pubmed: 31099694
Blood Cancer J. 2020 Feb 6;10(2):15
pubmed: 32029707
Stat Med. 2008 May 30;27(12):2037-49
pubmed: 18038446
Hemasphere. 2019 Mar 29;3(2):e191
pubmed: 31723828
Cell Death Differ. 2004 Jul;11 Suppl 1:S45-55
pubmed: 15243581
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Lancet Oncol. 2015 Jan;16(1):57-66
pubmed: 25524800
Blood. 2021 Jun 10;137(23):3272-3276
pubmed: 33534891
Hematol Oncol. 2019 Jun;37 Suppl 1:48-52
pubmed: 31187535
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
Blood Adv. 2020 Aug 25;4(16):3943-3951
pubmed: 32822484